Spots Global Cancer Trial Database for Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI
Official Title: A Single-arm, Open-label, Phase 1b Study Evaluating the Efficacy and Safety of Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI
Study ID: NCT04510415
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of olmutinib 600 mg QD in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).
Detailed Description: This is a single-arm, open-label, Phase 1b study to evaluate the efficacy and safety of oral single agent olmutinib administered to patients with T790M-positive NSCLC after treatment with an EGFR-TKI.
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
National Cancer Center, Gyeonggi-do, , Korea, Republic of
The Catholic Univ. of Korea Bucheon St.Mary's Hospital, Gyeonggi-do, , Korea, Republic of
The Catholic Univ. of Korea St.Vincent's Hospital, Gyeonggi-do, , Korea, Republic of
The Catholic Univ. of Korea Uijeongbu St.Mary's Hospital, Gyeonggi-do, , Korea, Republic of
Gachon University Gil Medical Center, Incheon, , Korea, Republic of
The Catholic Univ. of Korea Incheon St.Mary's Hospital, Incheon, , Korea, Republic of
Samsung Medical Center, Seoul, , Korea, Republic of
The Catholic Univ. of Korea Seoul St.Mary's Hospital, Seoul, , Korea, Republic of
Contact Details
Name: Hanmi Pharmaceuticals
Affiliation: Hanmi Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
